BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. CMPX, a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results. “Enrollment in our Phase 2/3 study, COMPANION-002, in patients with advanced BTC has increased in the…Read More
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Compass Therapeutics NASDAQCMPX
